Ketamine and its enantiomer esketamine occupy a somewhat different regulatory and trial design position than the newer wave of psychedelic-assisted therapy compounds, partly because…
Ketamine and its enantiomer esketamine occupy a somewhat different regulatory and trial design position than the newer wave of psychedelic-assisted therapy compounds, partly because ketamine’s approval as an anesthetic decades ago and its more established clinical use pattern give sponsors a different starting evidentiary base to build from.
The dissociative and perceptual effects of ketamine create blinding challenges similar in kind to those seen in psilocybin and MDMA trials, since patients and raters can often correctly guess treatment assignment based on the acute subjective experience, but the field has accumulated more clinical experience managing this specific challenge given ketamine’s longer history of therapeutic use in depression research.
Dosing route adds a layer of complexity not shared with orally administered psychedelic compounds, since ketamine trials must account for intravenous, intranasal, and other administration routes that each carry different pharmacokinetic profiles and different practical requirements for monitoring during the acute dosing period, affecting both trial design and the infrastructure required at trial sites.
Durability of effect has become a central focus of more recent ketamine trial design, since the compound’s rapid antidepressant effect is well established from earlier research, but sustaining that benefit beyond the initial post-dose window has proven more difficult, driving trial designs that specifically test maintenance dosing schedules and combination approaches with standard antidepressants or psychotherapy.
Abuse potential and controlled substance status shape ketamine trial operational requirements in ways that differ from standard CNS trials, requiring specific site-level controlled substance handling protocols and patient monitoring procedures that add operational complexity beyond what a typical outpatient depression trial would require.
Intel Brief coverage tracking how ketamine and esketamine trial programs are addressing durability of effect and administration route trade-offs, such as the analysis published by The Clinical Trial Vanguard, gives sponsors in this space a clearer view of where the field’s current design challenges and emerging solutions actually stand.
